Biotest Aktiengesellschaft (0N6Z.L)
| Previous close | 42.90 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | 15.485M |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.37 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Biotest AG: First patient treated with Cytotect® CP Biotest in study after heart and lung transplantation
EQS-News: Biotest AG / Key word(s): StudyBiotest AG: First patient treated with Cytotect® CP Biotest in study after heart and lung transplantation 24.01.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE First patient treated with Cytotect® CP Biotest in study after heart and lung transplantation High medical need due to severe cytomegalovirus (CMV) infections and resulting mortality after organ transplantation Study will provide data to opt
- EQS Group
Biotest AG: Biotest receives 'Innovation Champion of Sustainability' award
EQS-News: Biotest AG / Key word(s): MiscellaneousBiotest AG: Biotest receives 'Innovation Champion of Sustainability' award 19.01.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest receives "Innovation Champion of Sustainability" award Biotest achieves very good 5th place in sustainability analysis by F.A.Z.-Institute With its GoFuture sustainability initiative, Biotest aims to grow in line with social and ecological requirements. Dr
- EQS Group
Biotest AG: Biotest treats first COVID-19 patients with trimodulin in TRICOVID phase III trial
EQS-News: Biotest AG / Key word(s): StudyBiotest AG: Biotest treats first COVID-19 patients with trimodulin in TRICOVID phase III trial 10.01.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement.PRESS RELEASE Biotest treats first COVID-19 patients with trimodulin in TRICOVID phase III trial Trimodulin is a worldwide unique, innovative human plasma protein preparation in advanced development Significant reduction in clinical deterioration and mortality expect
